13.03.2017
Vita 34 AG DE000A0BL849
DGAP-News: Vita 34 AG Achieves Strongest Growth Since 2010
DGAP-News: Vita 34 AG / Key word(s): Final Results/Preliminary Results
Vita 34 AG Achieves Strongest Growth Since 2010
13.03.2017 / 07:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Vita 34 AG Achieves Strongest Growth Since 2010
- Revenues increase by 15 percent as compared to prior year to EUR 16.3
million
- Profitability significantly increased: EBITDA margin exceeds internal
prognosis by 14.1 percent
- Management Board proposes dividend of EUR 0.16 per share
Leipzig, 13 March 2017 - Vita 34 AG (WKN A0BL84) continued its growth trend
successfully in fiscal year 2016. Sales revenues increased by 15.0 percent
to EUR 16.3 million following EUR 14.2 million the previous year. The
positive revenue trend can also be attributed to the successful integration
of the companies acquired in 2015, as well as the geographic expansion of
Vita 34 in new markets. Vita 34 was able to further expand its position as
the second largest umbilical cord blood bank in Europe in the past fiscal
year.
The EBITDA margin of 14.1 percent was significantly higher than the target
range of 8 to 12 percent for fiscal year 2016.
EBITDA in the reporting period was EUR 2.3 million (fiscal year 2015
adjusted for one-time acquisition-related effects: EUR 0.8 million). EBIT of
EUR 0.8 million was also clearly higher than the prior year's value, which
adjusted for one-time acquisition-related effects was EUR -1.5 million. The
improved profitability was also reflected in a disproportionally higher
gross profit of EUR 8.6 million, which exceeded the prior year's value of
EUR 6.5 million by 32 percent.
The balance sheet total as of the closing date was EUR 43.4 million (prior
year: EUR 42.8 million). The equity ratio of 54.5 percent remained nearly
unchanged (prior year: 54.3 percent).
"These key indicators document the success of our Buy and Build strategy,
which is targeted towards realizing synergies and economies of scale. We
were able to complete the integration of the acquired companies to a great
extend, we have secured our position as market leader in the DACH countries
[Germany, Austria, Switzerland], and have clearly expanded it amongst the
top 10 umbilical cord blood banks worldwide. With the increasing successes
and advances of this strategy, the company is on the right path," commented
Dr. Andre Gerth, Chairman of the Management Board of Vita 34 AG, which is
publishing preliminary figures for fiscal year 2016 today.
The number of newly stored stem cell deposits from umbilical cord blood and
tissue has also increased significantly in the course of external growth. It
rose to a total of 155,000 stem cell deposits as of the end of 2016 (prior
year: 145.000). Apart from organic growth in the existing markets, another
contributing factor was that the company successfully pursued its
internationalization. Vita 34 obtained its first access to the market in the
Middle East via new cooperation partners in Dubai and Lebanon. Thanks to
cooperation with the Chinese technology company AVIC biology, which foresees
the joint construction of a stem cell bank in Yinchuan, in accordance with
the highest standards of quality, Vita 34 is now also active in the most
populous economy in the world and the most attractive market in Asia. The
company became active in Norway for the first time during the past fiscal
year via StemCare ApS, which was acquired in 2015. Vita 34 is now
represented in 28 countries worldwide apart from Germany.
A series of additional measures that were implemented in fiscal year 2016
are ensuring the successful continuation of the growth course set. This
includes the introduction of the "VitaMeins&Deins" [VitaMine&Yours] product,
where the umbilical cord blood collected at birth is divided into a personal
deposit for the child and a second deposit as a donation, if there is enough
volume. In this way the product combines the advantages that a stem cell
deposit offers, with the possibility of a donation. The high level of demand
for this new product shortly after its market launch documents the success
of Vita 34 development activities.
Dr. André Gerth provided the following outlook for the current fiscal year.
"The year 2017, in which we will celebrate our 20th anniversary, will be
characterized by the further integration of our subsidiaries. We will pursue
our expansion course consistently. We want to expand our market presence in
the DACH region more strongly and sustainably solidify our leading market
position. At the same time, the Management Board proposes to pay a dividend
in the amount of EUR 0.16 per share for 2016."
Overall, the Management Board of Vita 34 expects an increase in revenue of 7
to 10 percent and a continuing stable and high EBITDA margin of some 15
percent thanks to the expansion of the sales regions and even greater
penetration of existing markets. Total operating revenues in the current
year are expended to be at the prior year's level, corrected for special
effects, which is equivalent to an increase of approx. 3 percent.
All figures correspond with the preliminary status of the annual audit and
may change slightly after the audit operations have been concluded. The
complete Annual Report 2016 will be available for download as of 30 March
2017 on the Internet at www.vita34group.de in the Investor Relations
section.
2016 Key Figures
2016 2015 2014
CONSOLIDATED STATEMENT OF PROFIT AND
LOSS
Total Operating Revenue EUR 18,129 18,528 15,176
'000
Revenues EUR 16,290 14,169 13,786
'000
Gross Profit EUR 8,620 6,488 7,875
'000
EBITDA EUR 2,293 3,895 2.775
'000
EBITDA Margin (on Revenues) % 14.1 27.5 20.1
Operating Profit/EBIT EUR 780 1,613 1,690
'000
Earnings for the Period EUR 617 1,702 990
'000
Earnings per Share EUR 0.14 0.67 0.37
BALANCE SHEET / CASHFLOW
Balance sheet total EUR 43,422 43,782 37,056
'000
Equity EUR 23,648 23,756 22,160
'000
Equity Ratio % 54.5 54.3 59.8
Cash and cash equivalents EUR 2,813 2,082 3,730
'000
Investments EUR 566 4,656 424
'000
Depreciation and amortization EUR 1,513 2,282 1,085
'000
Cash flow from operating activities EUR 2,287 2,590 1,055
'000
PERSONNEL
Employees (as of Dec. 31) No. 122 140 105
Personnel expense EUR 6,330 5,620 4,886
'000
Company Profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank
in Europe and, as a complete provider, offers collection logistics,
preparation and storage of umbilical cord blood. The basis for its
successful work is an outstanding position in the technological segment of
cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC
for long periods of time, and can be used if needed in the context of
medical treatment. More than 155,000 customers throughout Europe are already
taking advantage of this offering and have provided for their children with
a stem cell deposit at Vita 34.
---------------------------------------------------------------------------
13.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: [email protected]
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
553087 13.03.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Vita 34 AG ISIN: DE000A0BL849 können Sie bei EQS abrufen
Biotechnologie , A0BL84 , V3V , XETR:V3V